491 related articles for article (PubMed ID: 17786611)
21. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
Kitsukawa K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
[TBL] [Abstract][Full Text] [Related]
22. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
23. Induction of lymphokine-activated cytotoxic T lymphocytes stimulated by dendritic cells and autologous tumor from a patient with gastric cancer and their effects in vitro.
Yoshikawa T; Yanoma S; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2005; 52(61):289-92. PubMed ID: 15783052
[TBL] [Abstract][Full Text] [Related]
24. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
25. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
26. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
27. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
28. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
[TBL] [Abstract][Full Text] [Related]
29. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture.
Foster AE; Forrester K; Gottlieb DJ; Barton GW; Romagnoli JA; Bradstock KF
Biotechnol Bioeng; 2004 Jan; 85(2):138-46. PubMed ID: 14704996
[TBL] [Abstract][Full Text] [Related]
30. Impact of culture medium on the expansion of T cells for immunotherapy.
Sato K; Kondo M; Sakuta K; Hosoi A; Noji S; Sugiura M; Yoshida Y; Kakimi K
Cytotherapy; 2009; 11(7):936-46. PubMed ID: 19903105
[TBL] [Abstract][Full Text] [Related]
31. Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells.
Curiel TJ; Krug EC; Purner MB; Poignard P; Berens RL
J Immunol; 1993 Aug; 151(4):2024-31. PubMed ID: 8102155
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
34. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
[TBL] [Abstract][Full Text] [Related]
35. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.
Mackensen A; Wittnebel S; Veelken H; Noppen C; Spagnoli GC; Lindermann A
Eur Cytokine Netw; 1999 Sep; 10(3):329-36. PubMed ID: 10477389
[TBL] [Abstract][Full Text] [Related]
36. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
Ding W; Fong C
Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
[TBL] [Abstract][Full Text] [Related]
37. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
Glazyrin AL; Kan-Mitchell J; Mitchell ML
Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
[TBL] [Abstract][Full Text] [Related]
38. [Development of specific immunotherapy for cancer].
Fujimoto S; Araki K; Hamasato S; Maeda N; Noguchi Y
Hum Cell; 1992 Sep; 5(3):247-55. PubMed ID: 1467324
[TBL] [Abstract][Full Text] [Related]
39. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy.
Rasmussen AM; Borelli G; Hoel HJ; Lislerud K; Gaudernack G; Kvalheim G; Aarvak T
J Immunol Methods; 2010 Apr; 355(1-2):52-60. PubMed ID: 20171968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
